Ranbaxy

Ranbaxy Laboratories Limited To become a Research based International Pharmaceutical Company Presented By: Aniruddha Nayak Roll- 7 PGDM- II (Since 1961)

Key Drivers of Pharma Growth ,[object Object],[object Object],[object Object],[object Object],[object Object],France Spain Italy Russia South Africa India $ Bn Value of Drugs going off patent 2006 - 11 Source : IMS ,[object Object]

Key Issues ,[object Object],[object Object]

Consolidation - Changing Landscape

The India Pharma Story Source – Financial Times

The Indian Pharmaceutical Industry today is in the front rank of India’s science-based industries . The Indian Pharma Industry is estimated to be worth $ 4.5 billion, growing at about 8 to 9 percent annually. The Indian Pharmaceutical sector is highly fragmented with more than 20,000 registered units Several Indian pharmaceutical companies have acquired companies in the US and Europe and many others .

Ranbaxy Today ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],$ 553 $ 972 $ 1339 CAGR 19 % Global Sales Worldwide Presence

[object Object],[object Object],[object Object],[object Object],[object Object]

MISSION:- “To become a research based international pharmaceutical company”. VISION:- Achieving customer satisfaction is fundamental to our business. Provide product and service of the highest quality. Manage our operation with high concern for strategy and environment. Be a responsible corporate citizen.

India ,[object Object],[object Object],[object Object],[object Object],[object Object],Source : ORG – IMS Audit Nov 2006, Moving Quarter Basis GSK Cipla Ranbaxy 5.0% 4.9% 5.1% Source : IMS - ORG First to market 10 NDDS 6 In-licensed 8

Research & Development New R&D facility for Drug Discovery Research (DDR) R&D I R&D III R&D II R&D IV

Research & Development ,[object Object],[object Object],[object Object],[object Object],[object Object],Alliance / Collaboration in DDR Out-licensing in NDDS Out-licensing in DDR

Ranbaxy – GSK Collaboration ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Proof of Concept

Major Acquisitions & Alliances ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],* Subject to due diligence

Niche Alliances ,[object Object],[object Object],Fermentation based products Bio-similars & Oncologics Peptides Krebs Zenotech Jupiter* * Subject to due diligence

BRAND RANBAXY OPINION OF DOCTORS TOWARDS RANBAXY PRODUCTS QUALITY

Ranbaxy Brands • Analgesics • Anti-Peptic Ulcerants • Cardiovasculars • Cephalosporins • CNS • Combination Therapy • Cough Preparations & Anti-Histamines • Dermatologicals • Diagnostic Instruments • Nutritionals • Oral Anti-Diabetics • Orthopaedic Segment • Other Anti-Infectives • Others • Quinolones • Reagents-Biochemistry • Reagents-Cardiac Markers • Reagents-HIV/Hepatitis • Reagents-Serology • Reagents-Torch Range • Semi-Synthetic Penicillins

Repositioning Ranbaxy ,[object Object],[object Object],[object Object]

[object Object],[object Object],[object Object],[object Object],‘ Revital’ising the brand

In Summary ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Ranbaxy

Empfohlen

Empfohlen

Weitere ähnliche Inhalte

Was ist angesagt?

Was ist angesagt? (20)

Andere mochten auch

Andere mochten auch (8)

Ähnlich wie Ranbaxy

Ähnlich wie Ranbaxy (20)

Ranbaxy